<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460445</url>
  </required_header>
  <id_info>
    <org_study_id>PI14/00649</org_study_id>
    <nct_id>NCT02460445</nct_id>
  </id_info>
  <brief_title>Phlebotomy and Polycystic Ovary Syndrome</brief_title>
  <official_title>Effect of Decreasing Iron Tissue Depots on the Cardiovascular Risk of Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manuel Luque Ramírez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIMS To study the effects of the decrease in iron tissue depots after scheduled bloodletting
      on insulin sensitivity, carbohydrate metabolism, classic and non-classic cardiovascular risk
      factors in patients with functional hyperandrogenism (polycystic ovary syndrome &amp; idiopathic
      hyperandrogenism) on standard treatment with combined oral contraceptives (COC) according to
      usual clinical practice.

      METHODOLOGY

      Open label, controlled, parallel, prospective study of 12 months of duration, with 2
      randomized arms of follow-up:

      i) Intervention Group: Patients with functional hyperandrogenism on standard COC treatment
      randomly allocated to perform scheduled phlebotomies from the third month of treatment to the
      end of the study (3 times with a 3-month interval between them).

      ii) Control Group: Patients with functional hyperandrogenism on standard COC treatment
      randomly allocated to follow-up without bloodletting.

      The whole group of patients will undergo a comprehensive anthropometric and hormonal
      assessment, evaluation of classic cardiovascular risk factors (insulin sensitivity and
      carbohydrate metabolism after a standard oral glucose test- 75 g), lipid profile, ambulatory
      and office blood pressure monitoring, proinflammatory profile, oxidative stress status,
      autonomic function assessment, and iron-related metabolism parameters at baseline, after
      3-month COC treatment and after reduction of iron tissue depots plus OC in the Intervention
      Group of patients, and throughout follow-up under treatment with COC in the Control Group of
      patients. If a significant relationship between circulating hepcidin levels and elevated
      ferritin concentrations is observed, a study of the potential influence of
      mutations/polymorphic variants of hepcidin gene on ferritin values will be performed as well.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Matsuda index from the circulating glucose and insulin concentrations during and standard oral glucose tolerance test.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with Hb &lt; 12 g/dl or hematocrit &lt;36% throughout the study</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the percentage of patients with undiagnosed prediabetes/diabetes between month 0 and 12 of follow-up</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Disposition index between month 0 and 12 of follow-up</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the lipid profile between month 0 and 12 of follow-up</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the blood pressure recordings between month 0 and 12 of follow-up</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ferropenia throughout the study</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a hypovolemic event during blood donation</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Subclinical chronic inflammation</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Autonomic vascular function</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood clotting test</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperandrogenism</condition>
  <condition>Metabolic Cardiovascular Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premenopausal women with functional hyperandrogenism under combined oral contraceptive pill qd as usual clinical practice who will undergo a scheduled standard phlebotomy every 3 months from month 3 to 12 of follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Premenopausal women with functional hyperandrogenism under standard combined oral contraceptive pill qd as usual clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phlebotomy</intervention_name>
    <description>Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Blood donation</other_name>
    <other_name>Bloodletting</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ethinylestradiol</intervention_name>
    <description>35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyproterone Acetate</intervention_name>
    <description>2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Premenopausal women with functional hyperandrogenism defined as:

               -  Polycystic ovary syndrome (PCOS): Clinical and biochemical hyperandrogenism plus
                  ovulatory dysfunction or polycystic ovarian morphology.

               -  Idiopathic hyperandrogenism: Clinical and biochemical hyperandrogenism with
                  normal ovulatory cycles and normal ovarian morphology.

          2. Combined oral contraceptive pill indication for treatment: i) hyperandrogenism-related
             dermo-cosmetic complaints with psychoemotional impact; ii) endometrial protection;
             and/or iii) contraception desire.

          3. Scheduled phlebotomy acceptation if randomly allocated.

          4. Signed informed consent.

        Exclusion Criteria:

          1. Contraindication for blood donation.

          2. Plasma ferritin &lt; 76 pmol/l and/or transferrin saturation percent &lt; 15%.

          3. Anemia (plasma hemoglobin &lt; 12 g/dl or hematocrit &lt; 36%).

          4. Chronic kidney disease (eGFR &lt; 60 ml/min per 1.73 m2).

          5. Personal history of dyslipidemia, hypertension, prediabetes, diabetes mellitus,
             gestational diabetes or cardiovascular events.

          6. Treatment with oral contraceptives, antiandrogens, insulin sensitizers, drugs that
             might interfere with blood pressure regulation, lipid profile or carbohydrate
             metabolism, and oral/parenteral iron therapy for the previous 3 months to inclusion.

          7. Previous surgical treatment for PCOS.

          8. History of blood donation for the previous 12 months to inclusion.

          9. Current history of infectious disease, inflammatory disease, liver disease, neurologic
             disease or malignancy.

         10. Eating disorders. Body mass index &lt; 18.5 Kg/m2.

         11. Hereditary hemochromatosis.

         12. Celiac disease or malabsorptive disorder.

         13. Contraindication for treatment with combined oral contraceptives.

         14. Pregnancy.

         15. Current smoking, recreational drug use or excessive alcohol consumption (&gt; 40 g per
             day).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Luque Ramírez, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant in Endocrinology. Member of the Diabetes, Obesity and Human Reproduction Research Group from the lnstituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Luque Ramírez, M.D., Ph. D.</last_name>
    <phone>0034913369029</phone>
    <email>manuel.luque@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Héctor F Escobar-Morreale, M.D., Ph.D.</last_name>
    <phone>0034913369029</phone>
    <email>hectorfrancisco.escobar@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Luque Ramírez, M.D., Ph.D.</last_name>
      <phone>0034913369029</phone>
      <email>manuel.luque@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Héctor F Escobar-Morreale, M.D., Ph.D.</last_name>
      <phone>0034913369029</phone>
      <email>hectorfrancisco.escobar@salud.madrid.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Manuel Luque Ramírez</investigator_full_name>
    <investigator_title>Member of the Diabetes, Obesity and Human Reproduction Research Group, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas CIBERDEM.</investigator_title>
  </responsible_party>
  <keyword>Functional hyperandrogenism</keyword>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>Idiopathic hyperandrogenism</keyword>
  <keyword>Iron tissue depots</keyword>
  <keyword>Phlebotomy</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Carbohydrate metabolism</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Autonomic dysfunction</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Blood clotting tests</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Side effects</keyword>
  <keyword>Randomized clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

